Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celcuity Inc. - Common Stock (NQ:CELC)

125.18 -0.46 (-0.37%)
Streaming Delayed Price Updated: 10:48 AM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celcuity Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology. 
Via The Motley Fool
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
Celcuity Inc. (NASDAQ:CELC) Reports Q4 Earnings Beat and Key FDA Priority Review for Gedatolisib ↗
Via Chartmill
Topics Earnings
Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In ↗
Via The Motley Fool
Discover the top movers in Monday's pre-market session. ↗
Via Chartmill
News headline image
Why Celcuity Stock Popped on Monday ↗
An analyst initiated coverage of the biotech. 
Via The Motley Fool
News headline image
Why Celcuity Stock Popped Today ↗
The cancer-focused biotech published its final set of figures for 2025. 
Via The Motley Fool
News headline image
The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026
As of March 24, 2026, the financial markets are witnessing a tectonic shift that many analysts have dubbed "The Great Rotation." For the first time in over a decade, the small-cap Russell 2000 index is... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗
Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals. 
Via The Motley Fool
News headline image
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing ↗
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Closes Position in GEO Stock, Sells $17.6 Million Worth of Shares, According to Recent SEC Filing ↗
This corrections firm delivers facility management and reentry services to government clients in the U.S., Australia, and South Africa. 
Via The Motley Fool
Topics Immigration Regulatory Compliance
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Great Rotation of 2026: Why Small-Cap 'Underdogs' are Finally Outpacing the Tech Titans
The first quarter of 2026 has ushered in a dramatic reversal of the decade-long market hierarchy. After years of trailing in the shadow of mega-cap technology giants, small-cap stocks—the perennial... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Apis Capital Expands Garrett Motion Stake as Hybrid Demand Extends the Combustion Cycle ↗
Apis Capital Advisors increased its stake in Garrett Motion, a key supplier of turbocharging systems used in combustion and hybrid vehicles. With global auto production still dominated by hybrid and... 
Via The Motley Fool
Topics Economy Emissions Regulatory Compliance
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment. 
Via The Motley Fool
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump ↗
Focused on targeted cancer therapies, this biotech firm reported a notable insider sale amid a year of extraordinary stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
From Equity Insider
Via GlobeNewswire
News headline image
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
3 Stocks You’ll Wish You Bought Before 2026 ↗
Via MarketBeat
News headline image
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗
One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results ↗
One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.